Compound · clinical trials

Gemcitabine clinical trials

Also listed in trial records as Gitrabin, LY188011, M^2, Gemcite, Gemcitabine Hydrochloride, NSC 613327, DFdCyd, LY 188011, Gemcitabin-GRY, DFdC, 1-(2-Oxo-4-amino-1

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 386 trials in our China, USA, Spain, Canada, South Korea, France, Japan, Australia, Italy, Germany, Taiwan, UK, Israel, Belgium, Poland, Mexico, Brazil, Netherlands, Turkey, Austria, Czechia, Singapore, Denmark, Switzerland, Norway, Ireland, India, Sweden, Portugal and Egypt registers that name Gemcitabine as an intervention. Synced 9 Nov 2026

386Current trials

204Recruiting now

196Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Gemcitabine is named as an intervention in 386 current clinical trials in our China, USA, Spain, Canada, South Korea, France, Japan, Australia, Italy, Germany, Taiwan, UK, Israel, Belgium, Poland, Mexico, Brazil, Netherlands, Turkey, Austria, Czechia, Singapore, Denmark, Switzerland, Norway, Ireland, India, Sweden, Portugal and Egypt registers. 204 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (20). The most-studied condition is Pancreatic Cancer. The EU clinical trials register (CTIS) separately lists 11 authorised or ongoing trials, 2 with a site in Ireland.

Where Gemcitabine is approved

All regulators →

Of the three regulators tracked here, the first to approve Gemcitabine was the US, on 15 May 1996. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)

15 May 1996

Gemzar

NDA020509 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

23 Dec 1996

Gemzar

Notice of Compliance 4428

First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Gemcitabine patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Gemcitabine, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

US FDA Orange Book Gemcitabine Hydrochloride, Avgemsi, Inlexzo

6 listed patents; the last listed expires 7 Nov 2038 (US 12636300).
Exclusivity NP: New product, until 9 Sep 2028.

See the Orange Book listing for NDA 200795

Patents and exclusivities above are pooled across 3 applications for this substance.

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Gemcitabine

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$884k

27,687 prescriptions in 2025 · Gemcitabine, Gemcitabine, gemcitabine

-33% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Gemcitabine works

All drug targets →

Ribonucleoside-diphosphate reductase RR1 inhibitor Inhibitor
Target: Ribonucleoside-diphosphate reductase RR1
✓ In ChEMBL and the Guide to Pharmacology
DNA polymerase (alpha/delta/epsilon) inhibitor Inhibitor
Target: DNA polymerase (alpha/delta/epsilon)
ChEMBL only

Diseases it has been tested for in clinical trials, by furthest phase

Immunoblastic LymphadenopathyPhase 3
Pancreatic cystsPhase 3
Ampulla of vater adenocarcinomaPhase 3
Biliary tract cancerPhase 3
Bladder transitional cell carcinomaPhase 3
Bone metastasisPhase 3
Breast cancerPhase 3
BronchitisPhase 3
CancerPhase 3
Carcinoma of the ampulla of vaterPhase 3

190 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL888, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 4793, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Gemcitabine

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 4 technology appraisals of Gemcitabine. 2 are current, and 2 of these recommend it for at least some patients. 2 older appraisals were replaced or withdrawn.

Appraisal	NICE recommendation	Published	Status
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer NICE TA389	Recommended Not recommended	27 Apr 2016	Current
Gemcitabine for the treatment of metastatic breast cancer NICE TA116	Recommended	24 Jan 2007	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Gemcitabine

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 9 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Gemcitabine

ATC code: L01BC05
ChEMBL: CHEMBL888
DrugBank: DB00441
PubChem CID: 60750
CAS number: 95058-81-4
FDA UNII: B76N6SBZ8R
Wikidata: Q414143
Wikipedia: Gemcitabine

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting20453%
Not yet open4612%
Active, closed13334%
By invitation31%

Trials by phase

Phase 214437%
Phase 313134%
Phase 1/24010%
Phase 1328%
Phase 2/3215%
Not applicable72%
Observational51%
Phase 441%
Early Phase 121%

Clinical trials of Gemcitabine

386 trials

Study	Phase	Status	Lead sponsor	Registers
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer NCT05035147 · Pancreatic Cancer	Phase 4	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer NCT06457503 · Nasopharyngeal Cancer Recurrent	Phase 4	Recruiting	Coherus Oncology, Inc	USA, Canada
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. NCT06820255 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer	Phase 4	Recruiting	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Italy
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer NCT07619235 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 4	Recruiting	Xianglin Yuan	China
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Norway, Mexico, Israel
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) NCT04365036 · ClinicalTrials.gov ↗ · NK/T Cell Lymphoma Nos	Phase 3	Recruiting	Sun Yat-sen University	China
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) NCT04574960 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Urothelial Carcinoma	Phase 3	Recruiting	University Health Network, Toronto	Canada
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer NCT04969731 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 3	Recruiting	GC Cell Corporation	South Korea
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma NCT05302284 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, HER2-expressing	Phase 3	Recruiting	RemeGen Co., Ltd	China
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature NCT05314998 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 3	Recruiting	John Neoptolemos	Germany, Sweden
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
Personalized Medicine for Advanced Biliary Cancer Patients NCT05615818 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms	Phase 3	Recruiting	UNICANCER	France, Belgium
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer NCT05754853 · ClinicalTrials.gov ↗ · Advanced or Metastatic Urothelium Cancer	Phase 3	Recruiting	Shanghai Miracogen Inc	China
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer NCT06017284 · ClinicalTrials.gov ↗ · Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting	Phase 3	Recruiting	Fudan University	China
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects NCT06079983 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 3	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) NCT06103864 · Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer NCT06156514 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy	Phase 3	Recruiting	National Institute of Cancerología	Mexico
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) NCT06170489 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response NCT06239727 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer NCT06255392 · ClinicalTrials.gov ↗ · Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer	Phase 3	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer NCT06268652 · ClinicalTrials.gov ↗ · Breast Cancer, Refractory Breast Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer NCT06282575 · Biliary Tract Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Israel
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137 · Non Small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer NCT06319820 · Non-Muscle Invasive Bladder Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Turkey, Brazil, Japan, South Korea, Israel
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer NCT06435429 · Metastatic HER2-positive Breast Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Canada, Brazil, Japan, South Korea, Australia
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 · Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06521255 · ClinicalTrials.gov ↗ · DLBCL	Phase 3	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd	China
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737 · Lymphoma	Phase 3	Recruiting	SecuraBio	UK, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer NCT06545955 · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	Phase 3	Recruiting	Ferring Pharmaceuticals	USA, France, Spain, Denmark, Poland, Czechia, Canada, South Korea
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer NCT06592326 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd	China
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma NCT06738251 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma	Phase 3	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. NCT06749899 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer	Phase 3	Recruiting	Sun Yat-Sen University Cancer Center	China
Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer NCT06752811 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic	Phase 3	Recruiting	Shanghai Yizhong Pharmaceutical Co., Ltd	China
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06792253 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	BeBetter Med Inc	China
PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma NCT06813976 · ClinicalTrials.gov ↗ · Ampullary Adenocarcinoma	Phase 3	Recruiting	Centre Hospitalier Universitaire Dijon	France
A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · Triple Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. NCT06897644 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Advanced or Metastatic	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer NCT06919965 · Non-Muscle Invasive Bladder Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Brazil, Japan, South Korea, Israel
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer NCT07079228 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study NCT07097142 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) NCT07165951 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Recruiting	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd	China
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer NCT07173751 · Breast Neoplasms	Phase 3	Recruiting	BioNTech SE	UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms	Phase 3	Recruiting	Eli Lilly and Company	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) NCT07229625 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) NCT07234162 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma	Phase 3	Recruiting	Dizal Pharmaceuticals	China, Taiwan
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer NCT07238283 · ClinicalTrials.gov ↗ · First-line Treatment of Metastatic Pancreatic Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) NCT07286266 · Ovarian Neoplasms	Phase 3	Recruiting	GlaxoSmithKline	UK, Canada, Japan, South Korea, Australia
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer NCT07418749 · ClinicalTrials.gov ↗ · Recurrent Cervical Cancer, Metastatic Cervical Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC NCT07424287 · ClinicalTrials.gov ↗ · NMIBC	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer NCT07436741 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Adult	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC NCT07459296 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Breast Cancer	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd	China
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc	UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Austria, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma NCT07498907 · ClinicalTrials.gov ↗ · Upper Tract Urothelial Carcinoma	Phase 3	Recruiting	Peking University First Hospital	China
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care NCT07533123 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer NCT07564141 · Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	USA, Japan
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) NCT07566156 · Urothelial Cancer, Urinary Bladder Neoplasms	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	USA, Canada, South Korea, Taiwan
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT07570823 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Phase 3	Recruiting	Sinocelltech Ltd	China
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China NCT07604766 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer	Phase 3	Recruiting	Genmab	China
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc	UK, USA, Italy, Netherlands, Austria
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) NCT07684612 · ClinicalTrials.gov ↗ · Ovarian Neoplasms	Phase 3	Recruiting	GlaxoSmithKline	Canada, Japan, South Korea, Australia
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC NCT07693959 · ClinicalTrials.gov ↗ · MIBC	Phase 3	Recruiting	Zhiquan Hu	China
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer NCT07710885 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Taiho Pharmaceutical Co., Ltd	Japan, South Korea, Australia
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) NCT07743164 · ClinicalTrials.gov ↗ · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	USA, Taiwan, Israel
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc	USA
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) NCT07829783 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Taiwan
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy NCT07869836 · ClinicalTrials.gov ↗ · Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer	Phase 3	Recruiting	SystImmune Inc	USA
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer NCT04628767 · ClinicalTrials.gov ↗ · Renal Pelvis and Ureter Urothelial Carcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017 · DLBCL, Diffuse Large B-Cell Lymphoma	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, France, Italy, Denmark, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer NCT05254171 · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV	Phase 2/3	Recruiting	Panbela Therapeutics, Inc	UK, USA, Germany, France, Spain, Italy, Belgium, Austria, South Korea, Australia
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence NCT06037980 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Cholangiocarcinoma	Phase 2/3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer NCT06361888 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 2/3	Recruiting	Hutchmed	China
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma	Phase 2/3	Recruiting	Vasgene Therapeutics, Inc	USA
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868 · Breast Neoplasms	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy NCT07106762 · Urothelial Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Japan, Australia, Israel
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma NCT07129993 · Urothelial Cancer, Bladder Cancer	Phase 2/3	Recruiting	Daiichi Sankyo	USA, China, Germany, France, Italy, Austria, Japan
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer NCT07544056 · ClinicalTrials.gov ↗ · Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer	Phase 2/3	Recruiting	BeBetter Med Inc	China
Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease NCT03101995 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Recruiting	National Institute of Cancerología	Mexico
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer NCT03498326 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Chemotherapy Effect	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma NCT04383119 · ClinicalTrials.gov ↗ · Leiomyosarcoma of Ovary, Soft Tissue Sarcoma	Phase 2	Recruiting	Italian Sarcoma Group	Italy
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery NCT04891289 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Memorial Sloan Kettering Cancer Center	Netherlands
Using ctDNA to Determine Therapies for Lung Cancer NCT04966663 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA	Phase 2	Recruiting	University Health Network, Toronto	Canada
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma NCT05180097 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada, Australia
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma NCT05548296 · Endometrial Adenocarcinoma	Phase 2	Recruiting	Acrivon Therapeutics	USA, Germany, France, Spain, Italy
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer NCT05601440 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer NCT05640791 · ClinicalTrials.gov ↗ · Resectable Biliary Tract Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949 · ClinicalTrials.gov ↗ · Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable	Phase 2	Recruiting	Beth Israel Deaconess Medical Center	Israel
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer NCT05725200 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Oslo University Hospital	Norway
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients NCT05821556 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Pancreas	Phase 2	Recruiting	National Cancer Institute, Naples	Spain, Italy
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer NCT05841420 · ClinicalTrials.gov ↗ · Pancreas Cancer, Non-Resectable Pancreas Carcinoma	Phase 2	Recruiting	Morten Ladekarl	Denmark
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer NCT05859750 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Akeso	China
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study NCT05934331 · ClinicalTrials.gov ↗ · Malignant Neoplasms of Digestive Organs	Phase 2	Recruiting	LaNova Medicines Zhejiang Co., Ltd	China
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects NCT05943379 · NMIBC	Phase 2	Recruiting	RemeGen Co., Ltd	China
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer NCT05999994 · Neoplasms, Child, Adolescent	Phase 2	Recruiting	Eli Lilly and Company	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Japan, Australia
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms	Phase 2	Recruiting	German Society for Pediatric Oncology and Hematology GPOH gGmbH	Germany
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270 · ClinicalTrials.gov ↗ · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Singapore, Australia
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) NCT06064097 · ClinicalTrials.gov ↗ · Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
Organoid-based Functional Precision Therapy for Advanced Breast Cancer NCT06102824 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Breast Cancer	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer NCT06111274 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer	Phase 2	Recruiting	Abbisko Therapeutics Co, Ltd	China
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer NCT06196788 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Fudan University	China
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors NCT06208462 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 · Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Poland, Canada, Japan, South Korea, Taiwan, Singapore, Australia
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer NCT06241781 · ClinicalTrials.gov ↗ · Adult	Phase 2	Recruiting	Grit Biotechnology	China
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) NCT06255210 · ClinicalTrials.gov ↗ · Olfactory Neuroblastoma	Phase 2	Recruiting	Hongmeng Yu	China
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients NCT06359275 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Fudan University	China
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy NCT06375915 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Francesco De Cobelli	Italy
The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Recruiting	National Cancer Center, Korea	South Korea
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. NCT06421298 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Jinghui Wang	China
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma NCT06440993 · ClinicalTrials.gov ↗ · Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA	Phase 2	Recruiting	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL NCT06489808 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-Cell Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer NCT06491472 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma NCT06583083 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	Phase 2	Recruiting	Sun Yat-sen University	China
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer NCT06591650 · ClinicalTrials.gov ↗ · Gallbladder Cancer Unresectable	Phase 2	Recruiting	Fudan University	China
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma NCT06696742 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer NCT06708858 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 2	Recruiting	Dai, Guanghai	China
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer NCT06710288 · Platinum-resistant Ovarian Cancer	Phase 2	Recruiting	ImmunityBio, Inc	USA
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma NCT06721286 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms NCT06767813 · ClinicalTrials.gov ↗ · Pancreatic Neoplasms	Phase 2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd	China
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer NCT06770439 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancers	Phase 2	Recruiting	Zhejiang University	China
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients NCT06770452 · Metastatic Pancreatic Carcinoma	Phase 2	Recruiting	Zhejiang University	China
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial NCT06770582 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033 · ClinicalTrials.gov ↗ · Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma	Phase 2	Recruiting	Hoffmann-La Roche	USA, Germany, France, Italy, Canada, South Korea, Australia
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. NCT06851247 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma NCT06854445 · ClinicalTrials.gov ↗ · Diffuse Large Cell B-lymphoma	Phase 2	Recruiting	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd	China
Probiotics in Advanced Urothelial Carcinoma NCT06904573 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy	Phase 2	Recruiting	Sun Yat-sen University	China
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer NCT06951997 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) NCT06960577 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate	Phase 2	Recruiting	AstraZeneca	France, Spain, Italy, Netherlands, Canada, Brazil, Australia
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer NCT07001618 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer NCT07007559 · Breast Cancer, Metastatic	Phase 2	Recruiting	ALX Oncology Inc	UK, USA, France, Spain, Italy, Canada, South Korea, Singapore
Chemoablation for Low-Grade Bladder Cancer NCT07019220 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer	Phase 2	Recruiting	Ekaterina Laukhtina	Austria
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma NCT07030140 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer	Phase 2	Recruiting	Jinbo Yue	China
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma NCT07036380 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 2	Recruiting	Centre Hospitalier Universitaire de Besancon	France
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma NCT07099547 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma	Phase 2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] NCT07111546 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC NCT07158489 · ClinicalTrials.gov ↗ · NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Swiss Cancer Institute	Switzerland
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer NCT07255404 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 2	Recruiting	BioNTech SE	China, Australia
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma NCT07259317 · ClinicalTrials.gov ↗ · Adenocarcinoma, Carcinoma, Pancreatic Ductal	Phase 2	Recruiting	Corcept Therapeutics	USA
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC NCT07296705 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC NCT07325539 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma NCT07359053 · ClinicalTrials.gov ↗ · Sarcoma	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
Cosiporfin Sodium for Injection Photodynamic Therapy NCT07398339 · ClinicalTrials.gov ↗ · Biliary Tract Cancers (BTC)	Phase 2	Recruiting	Shanghai Guangsheng Biopharmaceutical Co., Ltd	China
Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	Hospital Universitario Dr. Jose E. Gonzalez	Mexico
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680 · Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China, Germany, France, Spain, Italy, Belgium, Norway, Canada, Japan, South Korea
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer NCT07569679 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	Air Force Military Medical University, China	China
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC NCT07647289 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Peking University Third Hospital	China
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies NCT07668453 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC NCT07741448 · ClinicalTrials.gov ↗ · UTUC	Phase 2	Recruiting	Zhiquan Hu	China
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers NCT07769502 · Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	AbbVie	USA, China, Japan, Taiwan, Israel
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland, Canada
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Inhibrx Biosciences, Inc	USA, South Korea, Taiwan, Singapore
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 · Advanced Cancer, Metastatic Cancer, Ovarian Cancer	Phase 1/2	Recruiting	Artios Pharma Ltd	UK, USA, France, Spain
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) NCT05431270 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Phanes Therapeutics	USA
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) NCT05749900 · ClinicalTrials.gov ↗ · HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	Phase 1/2	Recruiting	Yonsei University	South Korea
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis	Phase 1/2	Recruiting	Institut de Recherches Internationales Servier	China, France, Spain, Italy, Denmark, Japan, Australia
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer NCT05827796 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Recruiting	InxMed (Shanghai) Co., Ltd	China
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer NCT05981001 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 1/2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer NCT06202261 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd	China
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Revolution Medicines, Inc	USA
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer NCT06460298 · Triple Negative Breast Cancer	Phase 1/2	Recruiting	ProDa BioTech, LLC	USA
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C NCT06821503 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd	China
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). NCT06843447 · Ovarian Cancer Recurrent	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, Spain, Switzerland, Canada, South Korea, Taiwan, Australia, Israel
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma NCT06956716 · ClinicalTrials.gov ↗ · Advanced Intrahepatic Cholangiocarcinoma	Phase 1/2	Recruiting	Zhejiang University	China
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer	Phase 1/2	Recruiting	Verastem, Inc	USA, France, Spain, Australia
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer NCT07049055 · Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Engeneic Pty Limited	USA
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma NCT07124936 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL)	Phase 1/2	Recruiting	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd	China
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies NCT07223047 · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Recruiting	Bristol-Myers Squibb	USA, Spain, Canada
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors NCT07229586 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy NCT07235202 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1/2	Recruiting	Shenzhen Majory Biotechnology Co., Ltd	China
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors NCT07296341 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Pancreatic Cancer With	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 1/2	Recruiting	Tongji Hospital	China
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer NCT07575191 · ClinicalTrials.gov ↗ · Pancreatic Cancer Non-resectable	Phase 1/2	Recruiting	Smartwise Sweden AB	Sweden
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation NCT07678593 · Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation	Phase 1/2	Recruiting	Genfleet Therapeutics (Shanghai) Inc	China, Australia
A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer NCT07701486 · ClinicalTrials.gov ↗ · Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the Pancreas	Phase 1/2	Recruiting	Theriva Biologics SL	Spain
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine NCT03854110 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1	Recruiting	Persevere Therapeutics Inc	USA, Israel
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer NCT04516447 · ClinicalTrials.gov ↗ · Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer	Phase 1	Recruiting	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	USA, South Korea, Australia
AB122 Platform Study NCT04999761 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer	Phase 1	Recruiting	Taiho Pharmaceutical Co., Ltd	Japan
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China, France, Spain, Japan, South Korea, Israel
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies NCT06181032 · ClinicalTrials.gov ↗ · Biliary Tract Malignancies	Phase 1	Recruiting	First Affiliated Hospital of Fujian Medical University	China
A Study of PHST001 in Advanced Solid Tumors NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer	Phase 1	Recruiting	Pheast Therapeutics	USA
Metastatic Nasopharyngeal Carcinoma NCT06886347 · ClinicalTrials.gov ↗ · Metastatic Nasopharyngeal Carcinoma	Phase 1	Recruiting	Chen Xiaozhong	China
BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA, Australia
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors NCT06983743 · Metastatic Solid Tumors	Phase 1	Recruiting	Erasca, Inc	USA, Canada, South Korea
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer NCT07024615 · Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients NCT07119996 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer	Phase 1	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies NCT07308132 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin	Phase 1	Recruiting	Janssen Research & Development, LLC	France, Spain, Belgium, Turkey, Australia
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma NCT07377045 · Pancreatic Adenocarcinoma Metastatic	Phase 1	Recruiting	Oncomatryx Biopharma S.L	USA, Spain, Israel
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma NCT06718257 · ClinicalTrials.gov ↗ · Cholangiocarcinoma	Observational	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study NCT07640048 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Observational	Recruiting	Peking Union Medical College Hospital	China
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer NCT04894643 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Proton Therapy	Not applicable	Recruiting	EBG MedAustron GmbH	Austria
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma NCT05352321 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Not applicable	Recruiting	Sun Yat-sen University	China
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma NCT05717790 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma by AJCC V8 Stage	Not applicable	Recruiting	Fourth Affiliated Hospital of Guangxi Medical University	China
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer NCT06494514 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer	Not applicable	Recruiting	Du Juan	China
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers NCT06611345 · ClinicalTrials.gov ↗ · Biliary Tract Cancers (BTC)	Not applicable	Recruiting	Jiangsu Healthy Life Innovation Medical Technology Co., Ltd	China
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer NCT06326736 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Early Phase 1	Recruiting	Jinling Hospital, China	China
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer NCT06217042 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 3	Not yet open	Fudan University	China
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes NCT07272109 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 3	Not yet open	Fudan University	China
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer NCT07383922 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 3	Not yet open	FutureGen Biopharmaceutical (Beijing) Co., Ltd	China
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma NCT07445295 · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Not yet open	Chipscreen Biosciences, Ltd	China
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. NCT07540390 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Not yet open	Sun Yat-sen University	China
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma NCT07691515 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 3	Not yet open	Zhejiang Cancer Hospital	China
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) NCT07783321 · Nasopharyngeal Carcinoma (NPC)	Phase 3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer NCT07797153 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 3	Not yet open	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer NCT07821606 · ClinicalTrials.gov ↗ · Platinum-sensitive Recurrent Ovarian Cancer	Phase 3	Not yet open	Hansoh BioMedical R&D Company	China
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer NCT07900789 · ClinicalTrials.gov ↗ · Systemic Treatment-naïve Pancreatic Cancer	Phase 3	Not yet open	Shanghai Hengrui Pharmaceutical Co., Ltd	China
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC NCT04890522 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Metastasis, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer NCT05562297 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer NCT06177522 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Neoadjuvant Therapy	Phase 2	Not yet open	Jinling Hospital, China	China
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids NCT06227065 · ClinicalTrials.gov ↗ · Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade	Phase 2	Not yet open	Hospital Centre Biel/Bienne	Switzerland
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients NCT06234072 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Not yet open	Shenzhen University General Hospital	China
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer NCT06361030 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors NCT06446388 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Not yet open	Qilu Pharmaceutical Co., Ltd	China
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) NCT06621095 · ClinicalTrials.gov ↗ · Pancreatic Cancer, First-line, Metastatic Pancreatic Cancer	Phase 2	Not yet open	RenJi Hospital	China
Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients NCT06623162 · ClinicalTrials.gov ↗ · Mibc, Muscle Invasive Bladder Cancer	Phase 2	Not yet open	Fundación de investigación HM	Spain
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma NCT06903273 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Biliary Tract Cancer (BTC)	Phase 2	Not yet open	National Cheng-Kung University Hospital	Taiwan
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment NCT07028424 · ClinicalTrials.gov ↗ · PDAC - Pancreatic Ductal Adenocarcinoma	Phase 2	Not yet open	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study NCT07189793 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder	Phase 2	Not yet open	First Affiliated Hospital of Wenzhou Medical University	China
Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma NCT07328802 · ClinicalTrials.gov ↗ · ORR,OS,PFS	Phase 2	Not yet open	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease NCT07420439 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)	Phase 2	Not yet open	Intergroupe Francophone de Cancerologie Thoracique	France
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma NCT07554482 · ClinicalTrials.gov ↗ · Extranodal NK/T-cell Lymphoma	Phase 2	Not yet open	Beijing Tongren Hospital	China
A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease. NCT07578337 · ClinicalTrials.gov ↗ · Untreated, Advanced Pancreatic Cancer	Phase 2	Not yet open	Nelum Corp	Spain
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07599423 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL)	Phase 2	Not yet open	The First Affiliated Hospital of Soochow University	China
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma NCT07768943 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma	Phase 2	Not yet open	Fudan University	China
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma NCT07774234 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma	Phase 2	Not yet open	The First Affiliated Hospital of Soochow University	China
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer NCT07776171 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	Phase 2	Not yet open	Sun Yat-sen University	China
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma NCT07797881 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. NCT07808567 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1	Phase 2	Not yet open	Gustave Roussy, Cancer Campus, Grand Paris	France
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma NCT07824856 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases	Phase 2	Not yet open	Sun Yat-sen University	China
Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer NCT07828756 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC NCT07833241 · ClinicalTrials.gov ↗ · Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma NCT07888621 · ClinicalTrials.gov ↗ · PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma NCT07902713 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	Sun Yat-sen University	China
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment NCT06370754 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. NCT06888674 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable	Phase 1/2	Not yet open	Zhejiang University	China
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. NCT07064863 · ClinicalTrials.gov ↗ · NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer	Phase 1/2	Not yet open	Queen's University	Canada
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC NCT07802184 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer	Phase 1/2	Not yet open	West China Hospital	China
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma NCT07818499 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 1/2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. NCT07348107 · ClinicalTrials.gov ↗ · Advanced Pancreatic Ductal Adenocarcinoma	Phase 1	Not yet open	Daniel Breadner	Canada
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion NCT07699757 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors	Phase 1	Not yet open	Haisco Pharmaceutical Group Co., Ltd	China
Combining Chemoradiotherapy With Sintilimab in First-Line ICC NCT06447454 · ClinicalTrials.gov ↗ · ICC	Observational	Not yet open	Shanghai Zhongshan Hospital	China
Canagliflozin With Gemcitabine in Pancreatic Carcinoma NCT05903703 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Not applicable	Not yet open	Zhang Xiaofeng,MD	China
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients NCT05947825 · ClinicalTrials.gov ↗ · PDAC - Pancreatic Ductal Adenocarcinoma	Phase 2	By invitation	Tianjin Medical University Cancer Institute and Hospital	China
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC NCT07353294 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Lymph Node Metastasis	Phase 1	By invitation	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients NCT06883136 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Observational	By invitation	Qianfoshan Hospital	China
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer NCT00565851 · ClinicalTrials.gov ↗ · Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Japan, South Korea
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer NCT02170090 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Gall Bladder Carcinoma	Phase 3	Active, closed	Universitätsklinikum Hamburg-Eppendorf	Germany, Italy, Netherlands, Denmark, Austria, Australia
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02446600 · ClinicalTrials.gov ↗ · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Japan, South Korea
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) NCT02453282 · Non-Small-Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Canada, Japan, South Korea, Taiwan, Australia
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT NCT02460887 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer NCT02516241 · Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) NCT02542293 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Sweden, Denmark, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Singapore, Israel
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) NCT03003962 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, China, Netherlands, Poland, Turkey, South Korea, Taiwan, Australia
Paediatric Hepatic International Tumour Trial NCT03017326 · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland, Germany, France, Spain, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Israel
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). NCT03164616 · Non Small Cell Lung Cancer NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, Poland, Brazil, Mexico, Japan, South Korea, Taiwan
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC NCT03257033 · Locally Advanced Pancreatic Cancer	Phase 3	Active, closed	RenovoRx	USA, Belgium
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) NCT03425643 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Egypt
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer NCT03456076 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Austria, Turkey, Japan, South Korea, Taiwan, Australia, Israel, Egypt
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer NCT03682068 · Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Spain, Italy, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC NCT03732677 · Muscle Invasive Bladder Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer NCT03775265 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer NCT03800134 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma NCT03967977 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	BeiGene	China, Taiwan
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer NCT04223856 · Urothelial Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Czechia, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185 · Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Japan, South Korea, Taiwan, Australia, Israel
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT04384484 · Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	ADC Therapeutics S.A	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, Israel
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT04408638 · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Belgium, Denmark, Poland, Switzerland, South Korea, Taiwan, Australia
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer NCT04579224 · ClinicalTrials.gov ↗ · Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) NCT04639986 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 3	Active, closed	Gilead Sciences	China, South Korea, Taiwan
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder NCT04658862 · Urinary Bladder Neoplasms	Phase 3	Active, closed	Janssen Research & Development, LLC	USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) NCT04700124 · Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma NCT04907370 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma NCT04974398 · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Akeso	USA, China, Canada, Brazil, Australia
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) NCT05104866 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma NCT05171647 · Non-Hodgkin Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	USA, China, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Israel
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma NCT05294172 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Recurrent or Metastatic	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer NCT05347134 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382286 · Triple Negative Breast Cancer, PD-L1 Positive	Phase 3	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382299 · Triple Negative Breast Cancer, PD-L1 Negative	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Intravesical BCG vs GEMDOCE in NMIBC NCT05538663 · ClinicalTrials.gov ↗ · Non-muscle-invasive Bladder Cancer	Phase 3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Egypt
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) NCT05587374 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer	Phase 3	Active, closed	Sun Yat-sen University	China
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) NCT05771480 · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Japan, South Korea, Singapore
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 NCT05911295 · Urothelial Carcinoma	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Sweden, Czechia, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) NCT06118333 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) NCT06211764 · Non-Muscle Invasive Bladder Neoplasms	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Brazil, Japan, South Korea
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma NCT06230224 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma (B-NHL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	Spain, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) NCT06343948 · ClinicalTrials.gov ↗ · HR+HER2- Breast Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) NCT06382142 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) NCT06459180 · Cervical Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT06508658 · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Genmab	UK, USA, China, France, Netherlands, Belgium, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer NCT06519370 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Active, closed	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd	China
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma NCT06608927 · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Arcus Biosciences, Inc	UK, USA, Germany, France, Spain, Italy, Belgium, Austria, Czechia, Canada, Japan, South Korea, Australia
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer NCT06619236 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer	Phase 3	Active, closed	Genmab	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Norway, Canada, Mexico, Japan, Australia, Israel
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) NCT06625320 · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Revolution Medicines, Inc	USA, Germany, France, Spain, Italy, Japan
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) NCT06629597 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	MediLink Therapeutics (Suzhou) Co., Ltd	China
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer NCT06632327 · ClinicalTrials.gov ↗ · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma NCT06929624 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA NCT02135042 · ClinicalTrials.gov ↗ · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7	Phase 2/3	Active, closed	NRG Oncology	China, Canada, Taiwan, Singapore, Australia
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature NCT02641847 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Breast Cancer	Phase 2/3	Active, closed	Fudan University	China
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers NCT02867865 · Gall Bladder Cancers	Phase 2/3	Active, closed	Tata Memorial Hospital	India
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552 · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT04442022 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 2/3	Active, closed	Karyopharm Therapeutics Inc	USA, China, Spain, Italy, Poland, Israel
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer NCT04559139 · ClinicalTrials.gov ↗ · Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8	Phase 2/3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) NCT05096663 · ClinicalTrials.gov ↗ · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8	Phase 2/3	Active, closed	SWOG Cancer Research Network	Mexico, Egypt
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer NCT06115499 · ClinicalTrials.gov ↗ · Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma	Phase 2/3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico, Egypt
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer NCT06783140 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation	Phase 2/3	Active, closed	University Health Network, Toronto	Canada
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) NCT07076121 · Pancreatic Ductal Adenocarcinoma	Phase 2/3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT01585805 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada, Israel
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma NCT01878617 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Active, closed	St. Jude Children's Research Hospital	Canada, Australia
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02101775 · Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada, Singapore
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer NCT02151084 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma, Gallbladder Carcinoma	Phase 2	Active, closed	University Health Network, Toronto	Canada
Pazopanib Vs. Pazopanib Plus Gemcitabine NCT02203760 · ClinicalTrials.gov ↗ · Leiomyosarcoma or Carcinosarcoma	Phase 2	Active, closed	North Eastern German Society of Gynaecological Oncology	Germany
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer NCT02299999 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	UNICANCER	France
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer NCT02340117 · Metastatic Pancreatic Cancer	Phase 2	Active, closed	SynerGene Therapeutics, Inc	USA
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma NCT02436707 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Active, closed	Canadian Cancer Trials Group	Canada
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02595892 · ClinicalTrials.gov ↗ · Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Israel
A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer NCT02632305 · ClinicalTrials.gov ↗ · Unresectable Biliary Tract Cancer	Phase 2	Active, closed	AHS Cancer Control Alberta	Canada
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer NCT02711553 · Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer	Phase 2	Active, closed	Eli Lilly and Company	UK, USA, China, Germany, France, Spain, Belgium, Sweden, Denmark, Austria, Czechia, Turkey, Mexico, South Korea, Taiwan, Australia
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer NCT03137771 · ClinicalTrials.gov ↗ · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer	Phase 2	Active, closed	NRG Oncology	Canada, Mexico, Israel
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread NCT03547973 · Metastatic Urothelial Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Turkey, Mexico, South Korea
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations NCT03609216 · ClinicalTrials.gov ↗ · Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma	Phase 2	Active, closed	Alliance for Clinical Trials in Oncology	Egypt
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) NCT03775486 · Non-small Cell Lung Cancer NSCLC	Phase 2	Active, closed	AstraZeneca	UK, USA, India, Netherlands, Belgium, Poland, Mexico, Japan, South Korea
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer NCT03816163 · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma	Phase 2	Active, closed	Astellas Pharma Global Development, Inc	Ireland, USA, China, France, Spain, Italy, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial NCT04216290 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread NCT04233866 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer NCT04274426 · Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	Phase 2	Active, closed	AGO Research GmbH	Germany
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer NCT04310007 · ClinicalTrials.gov ↗ · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT04390399 · Pancreatic Cancer	Phase 2	Active, closed	ImmunityBio, Inc	USA
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma NCT04543071 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma	Phase 2	Active, closed	Columbia University	Israel
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC NCT04630730 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Switzerland
Study of Lacutamab in Peripheral T-cell Lymphoma NCT04984837 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma, Relapse/Recurrence	Phase 2	Active, closed	The Lymphoma Academic Research Organisation	Germany, France, Spain, Belgium
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours NCT04999969 · Locally Advanced or Metastatic Solid Tumours	Phase 2	Active, closed	AstraZeneca	USA, Spain, Canada, South Korea
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids NCT05024734 · ClinicalTrials.gov ↗ · Bladder Cancer, Non-muscle Invasive	Phase 2	Active, closed	Roland Seiler-Blarer	Switzerland
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer NCT05026905 · ClinicalTrials.gov ↗ · Phase II, Open-label, Parallel 2-arm, Multi-center	Phase 2	Active, closed	National Health Research Institutes, Taiwan	China, Taiwan
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) NCT05451043 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer	Phase 2	Active, closed	AHS Cancer Control Alberta	Canada
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma NCT05524168 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC NCT05632328 · ClinicalTrials.gov ↗ · Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer	Phase 2	Active, closed	Bruno Bockorny	Israel
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer NCT05775159 · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Spain, Italy, Japan, South Korea, Taiwan
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma NCT05813626 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Zhejiang Cancer Hospital	China
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation NCT05975307 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy	Phase 2	Active, closed	Sun Yat-sen University	China
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) NCT06023862 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms	Phase 2	Active, closed	Yonsei University	Japan, South Korea, Taiwan, Singapore, Australia
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) NCT06225596 · Metastatic Urothelial Cancer	Phase 2	Active, closed	BicycleTx Limited	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients NCT06313970 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	Fudan University	China
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy NCT06449222 · Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers	Phase 2	Active, closed	BioNTech SE	UK, USA, Turkey, Australia
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer NCT06465563 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma NCT06492915 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 2	Active, closed	Chipscreen Biosciences, Ltd	China
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) NCT06632951 · Urothelial Carcinoma	Phase 2	Active, closed	AbbVie	USA, France, Spain, Poland, Canada, Japan, South Korea, Israel
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer NCT07005336 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	TJ Biopharma Co., Ltd	China
Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer NCT07806110 · ClinicalTrials.gov ↗ · Pancreas Ductal Adenocarcinoma	Phase 2	Active, closed	The First Hospital of Jilin University	China
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China, Germany, France, Spain, Italy, Denmark, South Korea, Taiwan, Israel
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors NCT04396821 · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	USA
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors NCT04495296 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	China
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8	Phase 1/2	Active, closed	Flemming Forsberg	Norway
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer NCT04827953 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 1/2	Active, closed	Nelum Corp	Spain
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer NCT05141149 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Active, closed	Prestige Biopharma Limited	USA, Spain, Singapore, Australia
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors NCT05229497 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1/2	Active, closed	Akeso	China
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation NCT06501625 · ClinicalTrials.gov ↗ · Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Phase 1/2	Active, closed	Institut de Recherches Internationales Servier	Germany, France, Spain, Canada, Brazil, Japan, South Korea, Australia
A Study of LY3200882 in Participants With Solid Tumors NCT02937272 · Solid Tumor	Phase 1	Active, closed	Eli Lilly and Company	USA, Germany, France, Spain, Italy, Canada, Japan, Australia
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies NCT03233139 · ClinicalTrials.gov ↗ · Advanced Malignancies	Phase 1	Active, closed	Regeneron Pharmaceuticals	Japan
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. NCT03252808 · ClinicalTrials.gov ↗ · Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV	Phase 1	Active, closed	Takara Bio Inc	Japan
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer NCT03816358 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC NCT03819465 · Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Active, closed	AstraZeneca	USA, Spain, Belgium, Poland, Austria, South Korea, Taiwan
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer NCT04491942 · ClinicalTrials.gov ↗ · Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations NCT04521686 · Cholangiocarcinoma, Chondrosarcoma, Glioma	Phase 1	Active, closed	Eli Lilly and Company	USA, China, France, Spain, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC NCT04947241 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy	Phase 1	Active, closed	Fifth Affiliated Hospital, Sun Yat-Sen University	China
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation NCT05919537 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor	Phase 1	Active, closed	Hummingbird Bioscience	Australia
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC NCT06059001 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 1	Active, closed	Peptomyc S.L	Spain
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) NCT06360354 · Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers	Phase 1	Active, closed	Amgen	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, Japan, Taiwan, Australia, Israel
CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) NCT06393400 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma	Phase 1	Active, closed	John Lenehan	Canada
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer NCT06532331 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors NCT06586515 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	Ireland, USA, China, Germany, France, Spain, Italy, Canada, Japan
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA, Germany, France, Spain, Italy, Belgium, Japan, Taiwan
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT06624085 · Lymphoma	Phase 1	Active, closed	Hoffmann-La Roche	USA
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) NCT04423731 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma	Observational	Active, closed	Oslo University Hospital	Norway
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma NCT04161248 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell	Early Phase 1	Active, closed	Canadian Cancer Trials Group	Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Gemcitabine in the EU trials register (CTIS)

11 trials · 2 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Gemcitabine. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
SAKK 18/25: Overcoming Resistance to Immunotherapy combining Gemcitabine with Ivonescimab in advanced NSCLC progressing on immune checkpoint inhibitors: A multicenter, single-arm, open-label phase II trial (ORIGIN2) 2026-526043-36-00 · Neoplasms	Phase 2	Authorised	Swiss Cancer Institute, Cancer Trials Ireland	Ireland
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2) 2025-522748-42-00 · Neoplasms	Phase 3	Ongoing	Incyte Corp	Ireland + 7 more
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL‑M07D1) vs. Platinum-based Chemotherapy in Patients with HER2‑expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy 2026-527617-29-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Systimmune Inc	Germany, Bulgaria, France + 2 more
A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevacizumab Compared with Platinum Doublet with Bevacizumab in Participants with Platinum-Sensitive Ovarian Cancer 2025-523366-24-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Glaxosmithkline Research & Development Limited	Czechia, Poland, Austria + 9 more
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309) 2025-524969-24-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Revolution Medicines Inc	Austria, Netherlands, Germany + 6 more
Pharmacokinetic study of pembrolizumab and its impact on immunity and the tumor microenvironment, which may explain the efficacy of post-immunotherapy chemotherapy - CPI 2026-526866-26-00 · Neoplasms	Phase 4	Authorised	Centre Antoine Lacassagne	France
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301) 2026-525617-31-00 · Neoplasms	Phase 3	Ongoing	Immuneering Corp	Spain, Czechia, Hungary + 6 more
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP) 2025-523055-55-00 · Neoplasms	Phase 2	Authorised	Universitaetsklinikum Heidelberg AöR	Germany
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours 2025-524620-22-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Orion Corporation	Finland, Denmark, Spain + 1 more
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02) 2025-522431-34-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Region Hovedstaden	Denmark
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease 2025-521884-12-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	BioNTech SE	Czechia, Poland, Italy + 5 more

Gemcitabine across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

9 single-substance products containing Gemcitabine on the HPRA medicines list.

Gemcitabine 38 mg/ml Concentrate for Solution for InfusionFresenius Kabi Deutschland GmbH · PA2059/039/005 · Marketed
Gemcitabine Teva 40 mg/ml Concentrate for Solution for InfusionTeva B.V. · PA1986/122/001 · Marketed
Gemcitabine 1 g Powder for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/092/002 · Not marketed
Gemcitabine 1 g powder for solution for infusionFresenius Kabi Deutschland GmbH · PA2059/039/002 · Not marketed
Gemcitabine 100 mg/ml Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/092/004 · Not marketed

All 9 Irish products →

Supply shortages

Bendacitabin 38 mg/mlGermany (BfArM) · Production problem · 4 Dec 2023 to 31 Jan 2027
Bendacitabin 38 mg/mlGermany (BfArM) · Production problem · 4 Dec 2023 to 31 Jan 2027
Bendacitabin 38 mg/mlGermany (BfArM) · Production problem · 4 Dec 2023 to 31 Jan 2027

EU shortages US shortages German shortages

Conditions studied with Gemcitabine

377 conditions

Pancreatic Cancer34 Pancreatic Ductal Adenocarcinoma18 Nasopharyngeal Carcinoma18 Biliary Tract Cancer12 Bladder Cancer9 PDAC - Pancreatic Ductal Adenocarcinoma9 Cholangiocarcinoma9 Metastatic Pancreatic Cancer8 Triple Negative Breast Cancer8 Ovarian Cancer7 Non-Small Cell Lung Cancer7 Urothelial Cancer6

All 377 conditions

Condition (as registered)	Trials
Pancreatic Cancer	34
Pancreatic Ductal Adenocarcinoma	18
Nasopharyngeal Carcinoma	18
Biliary Tract Cancer	12
Bladder Cancer	9
PDAC - Pancreatic Ductal Adenocarcinoma	9
Cholangiocarcinoma	9
Metastatic Pancreatic Cancer	8
Triple Negative Breast Cancer	8
Ovarian Cancer	7
Non-Small Cell Lung Cancer	7
Urothelial Cancer	6
Colorectal Cancer	6
Breast Cancer	6
Non-small Cell Lung Cancer	5
Urothelial Carcinoma	5
Urinary Bladder Neoplasms	5
Pancreatic Cancer Metastatic	5
PDAC	5
Non Small Cell Lung Cancer	5
Solid Tumor	5
Ovarian Neoplasms	4
Metastatic Pancreatic Ductal Adenocarcinoma	4
Advanced Cancer	4
Metastatic Urothelial Cancer	4
Advanced Solid Tumors	4
Bladder Urothelial Carcinoma	4
Nasopharyngeal Carcinoma (NPC)	4
Bladder (Urothelial, Transitional Cell) Cancer	4
Metastatic Breast Cancer	4
Intrahepatic Cholangiocarcinoma	4
Stage IV Pancreatic Cancer AJCC v8	4
Non-Muscle Invasive Bladder Neoplasms	3
Metastatic Pancreatic Adenocarcinoma	3
Breast Neoplasms	3
Diffuse Large B-Cell Lymphoma	3
Pancreatic Cancer Stage IV	3
Lymphoma	3
Platinum-resistant Ovarian Cancer	3
Pancreatic Ductal Adenocarcinoma (PDAC)	3
Locally Advanced Pancreatic Cancer	3
Biliary Tract Cancer (BTC)	3
Nasopharyngeal Cancer	3
Intrahepatic Cholangiocarcinoma (Icc)	3
Advanced Pancreatic Cancer	3
NMIBC	3
Stage III Pancreatic Cancer AJCC v8	3
Stage II Pancreatic Cancer AJCC v8	3
Cervical Cancer	2
Neoplasm Metastasis	2
Carcinoma, Non-Small-Cell Lung	2
Hepatoblastoma	2
Diffuse Large B-cell Lymphoma	2
Muscle Invasive Bladder Cancer	2
Non Small Cell Lung Carcinoma NSCLC	2
Gastric Cancer	2
Metastatic Cancer	2
Colorectal Cancer (CRC)	2
Melanoma	2
DLBCL	2
NSCLC	2
Muscle-Invasive Bladder Carcinoma	2
Metastatic Urothelial Carcinoma	2
Fallopian Tube Cancer	2
Peritoneal Cancer	2
Advanced Solid Tumor	2
Adenocarcinoma	2
Immunotherapy	2
Diffuse Large B Cell Lymphoma (DLBCL)	2
Advanced Biliary Tract Carcinoma	2
Advanced Urothelial Carcinoma	2
Hodgkin Lymphoma	2
Bile Duct Cancer	2
Biliary Tract Cancers (BTC)	2
Nasopharyngeal Cancinoma (NPC)	2
Pancreas Cancer	2
Pancreatic Neoplasms	2
Pancreatic Cancer Stage III	2
Biliary Tract Carcinoma	2
Chemotherapy Effect	2
Biliary Tract Neoplasms	2
Pancreatic Cancer Non-resectable	2
Neoadjuvant Therapy	2
Advanced Biliary Tract Cancer	2
Metastatic Nasopharyngeal Carcinoma	2
NSCLC (Advanced Non-small Cell Lung Cancer)	2
Adenocarcinoma of the Pancreas	2
Locally Advanced Pancreatic Adenocarcinoma	2
Stage II Bladder Cancer AJCC v8	2
Stage IIIA Bladder Cancer AJCC v8	2
Advanced Pancreatic Ductal Adenocarcinoma	2
Non-Muscle Invasive Bladder Urothelial Carcinoma	2
Fallopian Tube Clear Cell Adenocarcinoma	2
Stage IV Nasopharyngeal Carcinoma AJCC v8	2
Stage II Lung Cancer AJCC v8	2
Stage IIIA Lung Cancer AJCC v8	2
Pancreatic Adenocarcinoma	2
Advanced Malignancies	2
Fallopian Tube Neoplasms	1
Peritoneal Neoplasms	1
Carcinoma, Hepatocellular	1
Solid Tumors	1
Locally Advanced Breast Cancer	1
Metastatic Triple Negative Breast Cancers	1
PD-L1 Negative	1
Hepatocellular Carcinoma	1
Breast Cancer, Metastatic	1
Gastroesophageal Junction Cancer	1
Primary Peritoneal Cancer	1
PD-L1 Positive	1
Relapsed Diffuse Large B-Cell Lymphoma	1
Refractory Diffuse Large B-Cell Lymphoma	1
Non-small Cell Lung Cancer NSCLC	1
Neoplasms	1
Child	1
Adolescent	1
Ovarian Cancer Recurrent	1
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers	1
Malignant Solid Tumor	1
Non-Small Cell Lung Cancer (NSCLC)	1
Triple Negative Breast Neoplasms	1
Metastatic HER2-positive Breast Cancer	1
Non Small Cell Lung Cancer NSCLC	1
Head and Neck Cancer	1
CRC (Colorectal Cancer)	1
Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Epithelial Ovarian Cancer	1
Unresectable Locally Advanced Urothelial Cancer	1
CRC	1
Platinum-Sensitive Ovarian Cancer	1
Gastroesophageal-junction Cancer	1
Non-Small-Cell Lung Carcinoma NSCLC	1
Endometrial Cancer	1
Pancreatobiliary Cancers	1
Pancreatic Cancer, Metastatic	1
Solid Tumor, Adult	1
Advanced Solid Malignancies	1
Non-small Cell Lung Cancer (NSCLC)	1
Chondrosarcoma	1
Glioma	1
Any Solid Tumor	1
Lung Neoplasm Malignant	1
Non-Hodgkin Lymphoma	1
Bladder Cancer (BC)	1
Relapsed/Refractory Diffuse Large B-cell Lymphoma	1
Locally Advanced or Metastatic Solid Tumours	1
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	1
Metastatic Solid Tumors	1
Endometrial Adenocarcinoma	1
Nasopharyngeal Cancer Recurrent	1
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma	1
Carcinoma, Pancreatic Ductal	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
Pancreatic Adenocarcinoma Metastatic	1
Malignant Neoplam	1
Gall Bladder Cancers	1
Advanced Malignant Tumors	1
Metastasis	1
Chemotherapy	1
First-line Treatment of Metastatic Pancreatic Cancer	1
Lymph Node Metastasis	1
Peripheral T-cell Lymphoma	1
Muscle-Invasive Bladder Cancer (MIBC)	1
Nasopharyngeal Carcinoma by AJCC V8 Stage	1
UTUC	1
Programmed Cell Death Protein 1 Inhibitor	1
Radiotherapy	1
Sarcoma	1
Relapsed/Refractory Large B-Cell Lymphoma	1
Pancreatic Cancer Resectable	1
Lung Cancer	1
Locally Advanced or Metastatic Breast Cancer	1
Pancreatic Cancer, Adult	1
NK/T Cell Lymphoma Nos	1
HER2-negative Breast Cancer	1
Advanced Breast Cancer	1
Extranodal NK/T-cell Lymphoma	1
Advanced Pancreatic Cancers	1
Pancreatic Ductal Adenocarcinoma (mPDAC)	1
Probiotics	1
Advanced Solid Tumors Cancer	1
RAS Mutation	1
Olfactory Neuroblastoma	1
Carcinoma, Transitional Cell	1
Carcinoma in Situ of Bladder	1
Non-Muscle-Invasive Bladder Cancer	1
Hilar Cholangiocarcinoma	1
Resectable Biliary Tract Cancer	1
Upper Tract Urothelial Carcinoma	1
Phase II, Open-label, Parallel 2-arm, Multi-center	1
Locally Advanced or Metastatic Pancreatic Cancer With	1
Platinum Sensitive Ovarian Cancer (PSOC)	1
Pancreatic Cancer, Stage IB	1
Pancreatic Cancer, Stage IIA	1
Pancreatic Cancer, Stage IIB	1
Biliary Tract Malignancies	1
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	1
First-line	1
Triple-Negative Breast Cancer	1
Refractory Breast Carcinoma	1
Natural Killer/T-cell Lymphoma	1
Histiocytic Neoplasm	1
Histiocytosis	1
BRAF Gene Mutation	1
Advanced Intrahepatic Cholangiocarcinoma	1
Recurrent or Metastatic Cervical Cancer	1
Platinum-sensitive Recurrent Ovarian Cancer	1
PCNSL (Primary CNS Lymphoma)	1
Central Nervous System Lymphoma	1
Secondary Central Nervous System Lymphoma (SCNSL)	1
Pancreatic Ductal Adenocarcinoma, PDAC	1
Pancreas Ductal Adenocarcinoma	1
Muscle Invasive Bladder Cancer (MIBC)	1
Locally Advanced Head and Neck Squamous Cell Carcinoma	1
Nasopharangeal Cancer	1
Metastatic Pancreatic Carcinoma	1
DLBCL - Diffuse Large B Cell Lymphoma	1
Adult	1
HR+HER2- Breast Cancer	1
HER2-expressing	1
Chemotherapy-induced Nausea and Vomiting	1
ORR,OS,PFS	1
ICC	1
MIBC	1
Recurrent or Metastatic	1
Lung Metastases	1
Liver Metastases	1
Borderline Resectable Pancreatic Cancer	1
High-Risk Resectable Pancreatic Cancer	1
Malignant Neoplasms of Digestive Organs	1
Large B-Cell Lymphoma (LBCL)	1
High-grade B-cell Lymphoma	1
Extrahepatic Cholangiocarcinoma	1
Unresectable Perihilar or Ductal CCA	1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	1
Peripheral T Cell Lymphoma	1
Relapse/Recurrence	1
Leiomyosarcoma or Carcinosarcoma	1
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	1
Nasopharyngeal Neoplasms	1
Nasopharynx Cancer	1
Gall Bladder Carcinoma	1
Non Small Cell Lung Cancer Metastatic	1
Interstitial Lung Disease (ILD)	1
Immune Checkpoint Inhibitors	1
Methotrexate	1
Vinblastine	1
Ampullary Adenocarcinoma	1
Pancreatic Adenocarcinoma Resectable	1
Non Metastatic	1
ECOG Performance Status Score of 0 or 1	1
Lymphoma, Non-Hodgkin	1
B-Cell Non-Hodgkin Lymphoma (B-NHL)	1
Mibc	1
Untreated	1
Pancreas Cancer, Metastatic	1
Pancreas Cancer, Stage IV	1
Ductal Adenocarcinoma of the Pancreas	1
Leiomyosarcoma of Ovary	1
Soft Tissue Sarcoma	1
Pancreatic Adenocarcinoma Advanced or Metastatic	1
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable	1
Upper Tract Urothelial Cancer	1
Non-Resectable Pancreas Carcinoma	1
Non-muscle Invasive	1
Non-muscle Invasive Bladder Cancer	1
Low Grade	1
Proton Therapy	1
Metastatic Colorectal Cancer	1
Borderline Resectable Pancreatic Adenocarcinoma	1
Pancreatectomy	1
Muscle Invasive Bladder Carcinoma	1
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Stage I Bladder Cancer AJCC v8	1
Fallopian Tube Transitional Cell Carcinoma	1
Fallopian Tube Undifferentiated Carcinoma	1
Ovarian Clear Cell Adenocarcinoma	1
Recurrent Non-Small Cell Lung Carcinoma	1
Stage IV Non-Small Cell Lung Cancer	1
Gallbladder Carcinoma	1
Hepatocellular Cancer	1
Medulloblastoma	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Urothelial Carcinoma Bladder	1
Pancreatic Cancer, Advanced or Metastatic	1
BRCA1/2 Mutation	1
PALB2 Gene Mutation	1
Recurrent Nasopharyngeal Carcinoma	1
Stage II Nasopharyngeal Carcinoma AJCC v8	1
Stage III Nasopharyngeal Carcinoma AJCC v8	1
Muscle Invasive Bladder Urothelial Carcinoma	1
Complete Surgical Resection	1
Circulating Tumor DNA	1
Lymphoma, B-Cell	1
Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma	1
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma	1
Unresectable Biliary Tract Cancer	1
Non-muscle-invasive Bladder Cancer	1
Locally Advanced Cervical Cancer	1
Gemcitabine	1
Chemo-radiotherapy	1
Resectable Lung Non-Small Cell Carcinoma	1
Stage IIIB Lung Cancer AJCC v8	1
Pancreatic Acinar Cell Carcinoma	1
Pancreatic Adenosquamous Carcinoma	1
Pancreatic Carcinoma	1
Relapsed/Refractory Diffuse Large B Cell Lymphoma	1
Advanced Lung Non-Small Cell Carcinoma	1
Recurrent Lung Non-Small Cell Carcinoma	1
Stage III Lung Cancer AJCC v8	1
Endometrial Neoplasms	1
Uterine Cervical Neoplasms	1
Vulvar Cancer	1
Advanced or Metastatic Solid Tumor	1
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	1
Locally Advanced Solid Tumor	1
Metastatic Solid Tumor	1
Cholangiocarcinoma Non-resectable	1
Cholangiocarcinoma Metastatic	1
Ovarian Serous Tumor	1
Recurrent Fallopian Tube Carcinoma	1
Recurrent Ovarian Carcinoma	1
Recurrent Primary Peritoneal Carcinoma	1
EBV Infection	1
Stage II Nasopharyngeal Carcinoma AJCC v7	1
Stage III Nasopharyngeal Carcinoma AJCC v7	1
Stage IVA Nasopharyngeal Carcinoma AJCC v7	1
Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Squamous Carcinoma	1
Lung Non-Squamous Non-Small Cell Carcinoma	1
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	1
Stage II Lung Non-Small Cell Cancer AJCC v7	1
Stage IIA Lung Cancer AJCC v8	1
Stage IIB Lung Cancer AJCC v8	1
Locally Advanced Pancreatic Ductal Adenocarcinoma	1
Stage IIA Pancreatic Cancer AJCC v8	1
Advanced Bile Duct Carcinoma	1
Advanced Breast Carcinoma	1
Advanced Cervical Carcinoma	1
Advanced Endometrial Carcinoma	1
Ovarian Brenner Tumor	1
Ovarian Clear Cell Cystadenocarcinoma	1
Ovarian Endometrioid Adenocarcinoma	1
Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor	1
Stage III Bladder Cancer AJCC v8	1
Metastatic Bladder Urothelial Carcinoma	1
Refractory Bladder Urothelial Carcinoma	1
Refractory Urothelial Carcinoma	1
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma	1
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma	1
Stage IV Lung Cancer AJCC v8	1
Clear Cell Adenocarcinoma	1
Fallopian Tube Endometrioid Adenocarcinoma	1
Fallopian Tube Mucinous Adenocarcinoma	1
Renal Pelvis and Ureter Urothelial Carcinoma	1
Stage II Gallbladder Cancer AJCC v8	1
Stage IIA Gallbladder Cancer AJCC v8	1
Stage IIB Gallbladder Cancer AJCC v8	1
Stage III Gallbladder Cancer AJCC v8	1
Advanced or Metastatic Urothelium Cancer	1
Recurrent Breast Cancer	1
Relapsed/Refractory Diffuse Large B-Cell Lymphoma	1
Gallbladder Cancer Unresectable	1
Fludzoparib" and Anti-angiogenic	1
HRD-positive/HER2-negative Advanced Breast Cancer	1
Recurrent Cervical Cancer	1
Metastatic Cervical Cancer	1
Locally Advanced Triple-negative Breast Cancer	1
Metastatic Triple-negative Breast Cancer	1
Systemic Treatment-naïve Pancreatic Cancer	1
Diffuse Large Cell B-lymphoma	1
Advanced Solid Tumour	1
Infiltrating Bladder Urothelial Carcinoma	1
Stage II Bladder Urothelial Carcinoma	1
Stage III Bladder Urothelial Carcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	222	122
Clinical trials in USA	110	55
Clinical trials in Spain	83	33
Clinical trials in Canada	83	36
Clinical trials in South Korea	76	32
Clinical trials in France	75	32
Clinical trials in Japan	71	27
Clinical trials in Australia	70	32
Clinical trials in Italy	68	32
Clinical trials in Germany	60	24
Clinical trials in Taiwan	53	16
Clinical trials in UK	52	24
Clinical trials in Israel	50	18
Clinical trials in Belgium	47	18
Clinical trials in Poland	45	14
Clinical trials in Mexico	45	12
Clinical trials in Brazil	40	16
Clinical trials in Netherlands	34	14
Clinical trials in Turkey	33	10
Clinical trials in Austria	27	13
Clinical trials in Czechia	26	10
Clinical trials in Singapore	25	9
Clinical trials in Denmark	21	8
Clinical trials in Switzerland	19	7
Clinical trials in Norway	13	6
Clinical trials in Ireland	12	5
Clinical trials in India	12	4
Clinical trials in Sweden	11	6
Clinical trials in Portugal	10	3
Clinical trials in Egypt	7	0
EU register (CTIS)	11	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Gemcitabine trials

How many clinical trials are testing Gemcitabine?

386 current trials in our China, USA, Spain, Canada, South Korea, France, Japan, Australia, Italy, Germany, Taiwan, UK, Israel, Belgium, Poland, Mexico, Brazil, Netherlands, Turkey, Austria, Czechia, Singapore, Denmark, Switzerland, Norway, Ireland, India, Sweden, Portugal and Egypt registers name Gemcitabine (also registered as LY188011) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Gemcitabine trials recruiting patients?

Yes. 204 of the 386 trials are recruiting: 122 with sites in China, 55 with sites in USA, 33 with sites in Spain, 36 with sites in Canada, 32 with sites in South Korea, 32 with sites in France, 27 with sites in Japan, 32 with sites in Australia, 32 with sites in Italy, 24 with sites in Germany, 16 with sites in Taiwan, 24 with sites in UK, 18 with sites in Israel, 18 with sites in Belgium, 14 with sites in Poland, 12 with sites in Mexico, 16 with sites in Brazil, 14 with sites in Netherlands, 10 with sites in Turkey, 13 with sites in Austria, 10 with sites in Czechia, 9 with sites in Singapore, 8 with sites in Denmark, 7 with sites in Switzerland, 6 with sites in Norway, 5 with sites in Ireland, 4 with sites in India, 6 with sites in Sweden and 3 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Gemcitabine clinical trials?

Sun Yat-sen University (20), AstraZeneca (18), National Cancer Institute (NCI) (17) and Merck Sharp & Dohme LLC (13), among 196 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Gemcitabine clinical trials in Ireland?

Yes. 12 trials in our Ireland register (ClinicalTrials.gov), and 2 trials in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Gemcitabine licensed in Ireland?

Yes. The HPRA medicines list includes 9 single-substance products containing Gemcitabine, for example Gemcitabine 38 mg/ml Concentrate for Solution for Infusion (Fresenius Kabi Deutschland GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Gemcitabine shortage?

The registers we track list 3 entries for Gemcitabine: 3 German notices. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Gemcitabine works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gemcitabine works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gemcitabine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.